Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm Phase II Clinical Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma

NCT06423326 is registered in ClinicalTrials.gov with Georgetown University as lead sponsor.

NCT NCT06423326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06423326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm Phase II Clinical Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma
Lead sponsor
Georgetown University
Phase
Phase 2
Overall status
Recruiting
Start date
August 6, 2024
Completion date
December 31, 2027
Enrollment
36 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

borderline resectable pancreatic ductal adenocarcinoma, resectable pancreatic adenocarcinoma, stage i pancreatic cancer ajcc v8, stage ii pancreatic cancer ajcc v8, stage iii pancreatic cancer ajcc v8